Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 21, 2006

Actavis Enlarges Russian Presence

  • Actavis acquired a 51% controlling interest in ZiO Zdorovje, a Russian pharmaceutical manufacturer.
    Out of a total cost of $60 million for the deal, $30 million will be targeted for investment in the ZiO Zdorovje manufacturing site with the goals of creating a platform for increased production and capacity as well as introducing new products.

    The current owners of ZiO Zdorovje will retain a 49% stake in the business.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »